Potential clinical significance of plasma-based KRAS mutation analysis using the COLD-PCR/TaqMan®-MGB probe genotyping method

Liu,Peijia; Liang,Hongyan; Xue,Li; Yang,Chun; Liu,Yang; Zhou,Kun; Jiang,Xiaofeng

doi:10.3892/etm.2012.566

Potential clinical significance of plasma-based KRAS mutation analysis using the COLD-PCR/TaqMan®-MGB probe genotyping method

Authors:
- Peijia Liu
- Hongyan Liang
- Li Xue
- Chun Yang
- Yang Liu
- Kun Zhou
- Xiaofeng Jiang
View Affiliations

Affiliations: Department of Clinical Biochemistry Laboratory, The 4th Affiliated Hospital of Harbin Medical University, Harbin, P.R. China
Published online on: May 2, 2012 https://doi.org/10.3892/etm.2012.566
Pages: 109-112

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Despite the improved ability to detect mutations in recent years, tissue specimens cannot always be procured in a clinical setting, particularly from patients with recurrence of tumors or metastasis. Therefore, the aim of this study was to investigate whether plasma is able to be used for mutation analysis instead of tissue specimens. We collected plasma from 62 patients with colorectal cancer (CRC) prior to treatment. DNA extracted from plasma and matched tumor tissues were obtained. Mutations in KRAS were amplified from the tissue specimens and sequenced by regular polymerase chain reaction (PCR) and co-amplification at lower denaturation temperature (COLD)-PCR. Plasma KRAS gene mutation on codon 12 (GGT>GAT) was detected using a nested COLD-PCR/TaqMan®-MGB probe. Mutations in plasma and matched tumors were compared. KRAS mutation on codon 12 (GGT>GAT) was found in 13 (21.0%) plasma specimens and 12 (19.4%) matched tumor tissues. The consistency of KRAS mutations between plasma and tumors was 75% (9/12), which indicated a high correlation between the mutations detected in plasma DNA and the mutations detected in the corresponding tumor DNA (P<0.001; correlation index, k=0.649). Notably, four (6.5%) patients with plasma DNA mutations had no detectable KRAS mutations in the corresponding primary tumors, and three (4.8%) patients with tumor DNA mutations had no detectable KRAS mutations in the corresponding plasma DNA samples. Thus, KRAS mutations in plasma DNA correlate with the mutation status in matched tumor tissues of patients with CRC. Our study provides evidence to suggest that plasma DNA may be used as a potential medium for KRAS mutation analysis in CRC using the COLD-PCR/TaqMan-MGB probe method.

View Figures

View References

1	Solassol J, Ramos J, Crapez E, et al: KRAS mutation detection in paired frozen and formalin-fixed paraffin-embedded (FFPE) colorectal cancer tissues. Int J Mol Sci. 12:3191–3204. 2011. View Article : Google Scholar : PubMed/NCBI
2	Raymond E, Faivre S and Armand JP: Epidermal growth factor receptor tyrosine kinase as a target for anticancer therapy. Drugs. 60:15–23. 2000. View Article : Google Scholar : PubMed/NCBI
3	Lin JS, Webber EM, Senger CA, Holmes RS and Whitlock EP: Systematic review of pharmacogenetic testing for predicting clinical benefit to anti-EGFR therapy in metastatic colorectal cancer. Am J Cancer Res. 1:650–662. 2011.PubMed/NCBI
4	Mack PC, Holland WS, Burich RA, et al: EGFR mutations detected in plasma are associated with patient outcomes in erlotinib plus docetaxel-treated non-small cell lung cancer. J Thorac Oncol. 4:1466–1472. 2009. View Article : Google Scholar : PubMed/NCBI
5	Li J, Wang L, Mamon H, Kulke MH, Berbeco R and Makrigiorgos GM: Replacing PCR with COLD-PCR enriches variant DNA sequences and redefines the sensitivity of genetic testing. Nat Med. 14:579–584. 2008. View Article : Google Scholar : PubMed/NCBI
6	Milbury CA, Li J, Liu P and Makrigiorgos GM: COLD-PCR: improving the sensitivity of molecular diagnostics assays. Expert Rev Mol Diagn. 11:159–169. 2011. View Article : Google Scholar : PubMed/NCBI
7	Li J, Wang L, Jänne PA and Makrigiorgos GM: Coamplification at lower denaturation temperature-PCR increases mutation-detection selectivity of TaqMan-based real-time PCR. Clin Chem. 5:748–756. 2009. View Article : Google Scholar : PubMed/NCBI
8	Wang S, An T, Wang J, et al: Potential clinical significance of a plasma-based KRAS mutation analysis in patients with advanced non-small cell lung cancer. Clin Cancer Res. 16:1324–1330. 2010. View Article : Google Scholar : PubMed/NCBI
9	Li J, Milbury CA, Li C and Makrigiorgos GM: Two-round coamplification at lower denaturation temperature-PCR (COLD-PCR)-based sanger sequencing identifies a novel spectrum of low-level mutations in lung adenocarcinoma. Hum Mutat. 30:1583–1590. 2009. View Article : Google Scholar
10	Pritchard CC, Akagi L, Reddy PL, Joseph L and Tait JF: COLD-PCR enhanced melting curve analysis improves diagnostic accuracy for KRAS mutations in colorectal carcinoma. BMC Clin Pathol. 26:62010. View Article : Google Scholar : PubMed/NCBI
11	Boni L, Cassinotti E, Canziani M, Dionigi G, Rovera F and Dionigi R: Free circulating DNA as possible tumour marker in colorectal cancer. Surg Oncol. 1:29–31. 2007. View Article : Google Scholar : PubMed/NCBI
12	Bazan V, Bruno L, Augello C, et al: Molecular detection of TP53, Ki-Ras and p16INK4A promoter methylation in plasma of patients with colorectal cancer and its association with prognosis. Results of a 3-year GOIM (Gruppo Oncologico dell’Italia Meridionale) prospective study. Ann Oncol. 7:84–90. 2006.PubMed/NCBI
13	Kimura T, Holland WS, Kawaguchi T, et al: Mutant DNA in plasma of lung cancer patients: potential for monitoring response to therapy. Ann NY Acad Sci. 1022:55–60. 2004. View Article : Google Scholar : PubMed/NCBI
14	Trombino S, Neri M, Puntoni R, et al: Mutations in K-ras codon 12 detected in plasma DNA are not an indicator of disease in patients with non-small cell lung cancer. Clin Chem. 51:1313–1314. 2005. View Article : Google Scholar : PubMed/NCBI
15	Yung TK, Chan KC, Mok TS, Tong J, To KF and Lo YM: Single-molecule detection of epidermal growth factor receptor mutations in plasma by microfluidics digital PCR in non-small cell lung cancer patients. Clin Cancer Res. 15:2076–2084. 2009. View Article : Google Scholar : PubMed/NCBI
16	Maheswaran S, Sequist LV, Nagrath S, et al: Detection of mutations in EGFR in circulating lung-cancer cells. N Engl J Med. 359:366–377. 2008. View Article : Google Scholar : PubMed/NCBI
17	Mancini I, Santucci C, Sestini R, et al: The use of COLD-PCR and high-resolution melting analysis improves the limit of detection of KRAS and BRAF mutations in colorectal cancer. J Mol Diagn. 12:705–711. 2010. View Article : Google Scholar : PubMed/NCBI
18	Zuo Z, Chen SS, Chandra PK, et al: Application of COLD-PCR for improved detection of KRAS mutations in clinical samples. Mod Pathol. 22:1023–1031. 2009. View Article : Google Scholar : PubMed/NCBI
19	Milbury CA, Li J and Makrigiorgos GM: COLD-PCR-enhanced high-resolution melting enables rapid and selective identification of low-level unknown mutations. Clin Chem. 55:2130–2143. 2009. View Article : Google Scholar : PubMed/NCBI